Abstract
Disturbances in the circadian rhythms have long been associated with depression and mania. Animal models of mania and depression exhibit differential effects upon the intrinsic circadian period and the same occurs with antidepressants and mood stabilizers treatment. The intrinsic circadian period is expressed when there are no time clues or when the light/dark cycle length is beyond the capacity of synchronization. In summary, while there is no clear association between the circadian period and mania, depressive-like behaviour is generally associated either with lengthening of the circadian period or with arrythmicity, and the improvement of depressive-like behaviour is associated with shortening of the circadian period. Thus, this review is an attempt to summarize data regarding these correlations and find a putative role of the circadian intrinsic period in mood regulation, particularly concerning the switch from depression to mania.
Keywords: Antidepressants, bipolar disorder, depression, endogenous circadian period, mania, mood stabilizers.
CNS & Neurological Disorders - Drug Targets
Title:Stretch, Shrink, and Shatter the Rhythms: The Intrinsic Circadian Period in Mania and Depression
Volume: 14 Issue: 8
Author(s): Bruno Jacson Martynhak, Marcela Pereira, Camila Pasquini de Souza and Roberto Andreatini
Affiliation:
Keywords: Antidepressants, bipolar disorder, depression, endogenous circadian period, mania, mood stabilizers.
Abstract: Disturbances in the circadian rhythms have long been associated with depression and mania. Animal models of mania and depression exhibit differential effects upon the intrinsic circadian period and the same occurs with antidepressants and mood stabilizers treatment. The intrinsic circadian period is expressed when there are no time clues or when the light/dark cycle length is beyond the capacity of synchronization. In summary, while there is no clear association between the circadian period and mania, depressive-like behaviour is generally associated either with lengthening of the circadian period or with arrythmicity, and the improvement of depressive-like behaviour is associated with shortening of the circadian period. Thus, this review is an attempt to summarize data regarding these correlations and find a putative role of the circadian intrinsic period in mood regulation, particularly concerning the switch from depression to mania.
Export Options
About this article
Cite this article as:
Martynhak Jacson Bruno, Pereira Marcela, de Souza Pasquini Camila and Andreatini Roberto, Stretch, Shrink, and Shatter the Rhythms: The Intrinsic Circadian Period in Mania and Depression, CNS & Neurological Disorders - Drug Targets 2015; 14 (8) . https://dx.doi.org/10.2174/1871527314666150909115203
DOI https://dx.doi.org/10.2174/1871527314666150909115203 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Neuropeptides VIP / PACAP and T Cells: Inhibitors or Activators?
Current Pharmaceutical Design Determining Serum Levels of IL-10 and IL-17 in Patients with Low Back Pain Caused by Lumbar Disc Degeneration
Infectious Disorders - Drug Targets Adverse Effects of Antidepressants Reported by a Large International Cohort: Emotional Blunting, Suicidality, and Withdrawal Effects
Current Drug Safety Prediction Model of Early Return to Hospital after Discharge Following Acute Ischemic Stroke
Current Neurovascular Research Focal Adhesion Kinase Controls Prostate Cancer Progression Via Intrinsic Kinase and Scaffolding Functions
Anti-Cancer Agents in Medicinal Chemistry Endocannabinoid Blockade and the Cardiovascular System
Current Drug Therapy Melatonergic Drugs for Therapeutic Use in Insomnia and Sleep Disturbances of Mood Disorders
CNS & Neurological Disorders - Drug Targets Recent Progress and Challenges in Nanotechnology for Biomedical Applications: An Insight into the Analysis of Neurotransmitters
Recent Patents on Nanotechnology Genetic Vulnerability to Psychosis and Cortical Function: Epistatic Effects between DAAO and G72
Current Pharmaceutical Design Di- and Sesquiterpenoids from Cystoseira Genus: Structure, Intra-molecular Transformations and Biological Activity
Mini-Reviews in Medicinal Chemistry The Prevalence, Morbidities, and Treatments of Insomnia
CNS & Neurological Disorders - Drug Targets Inhibition of Tau Aggregation in Cell Models of Tauopathy
Current Alzheimer Research Light-Emitting Diode (LED) Therapy Attenuates Neurotoxicity of Methanol-Induced Memory Impairment and Apoptosis in The Hippocampus
CNS & Neurological Disorders - Drug Targets Synthesis and Preliminary Screening of Novel Tryptamines as 5-HT4 Receptor Ligands
Current Medicinal Chemistry Mambalgins, the Venom-origin Peptides as a Potentially Novel Group of Analgesics: Mini Review
CNS & Neurological Disorders - Drug Targets Extraction, Characterization and In Vivo Neuromodulatory Activity of Phytosterols from Microalga Dunaliella Tertiolecta
Current Medicinal Chemistry Insight into the Epigenetics of Alzheimer's Disease: A Computational Study from Human Interactome
Current Alzheimer Research The Neurobiological Bases for Development of Pharmacological Treatments of Aggressive Disorders
Current Neuropharmacology Vasoactive Factors and Diabetic Retinopathy: Vascular Endothelial Growth Factor, Cycoloxygenase-2 and Nitric Oxide
Current Pharmaceutical Design Effects of Thiazolidinediones Beyond Glycaemic Control
Current Pharmaceutical Design